Iron sucrose is a parenteral iron replacement indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). It is available as injection for intravenous and intravitreal use. MedsAcross supplies Iron sucrose for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Venofer is indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). Venofer is an iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD).
Source: US FDA prescribing information
Venofer is an aqueous complex of poly-nuclear iron (III)-hydroxide in sucrose. Following intravenous administration, Venofer is dissociated into iron and sucrose and the iron is transported as a complex with transferrin to target cells including erythroid precursor cells. The iron in the precursor cells is incorporated into hemoglobin as the cells mature into red blood cells.
Source: US FDA prescribing information
Venofer must only be administered intravenously either by slow injection or by infusion. The dosage of Venofer is expressed in mg of elemental iron. Each mL contains 20 mg of elemental iron. Population Dose Adult patients Hemodialysis Dependent-Chronic Kidney Disease (HDD-CKD) 100 mg slow intravenous injection or infusion Non-Dialysis Dependent-Chronic Kidney Disease (NDD-CKD) 200 mg slow intravenous injection or infusion Peritoneal Dialysis Dependent-Chronic Kidney Disease (PDD-CKD) 300 mg or 400 mg intravenous infusion Pediatric patients HDD-CKD, PDD-CKD or NDD-CKD 0.5 mg/kg slow intravenous injection or infusion
Source: US FDA prescribing information
Known hypersensitivity to Venofer.
Source: US FDA prescribing information
Hypersensitivity Reactions: Observe for signs and symptoms of hypersensitivity during and after Venofer administration for at least 30 minutes and until clinically stable following completion of each administration. Only administer Venofer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. Hypotension: May cause hypotension. Monitor for signs and symptoms of hypotension during and following each administration. Iron Overload: Regularly monitor hematologic responses during therapy. Do not administer to patients with iron overload.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions Hypotension Iron Overload Adult patients: The most common adverse reactions (≥2%) are diarrhea, nausea, vomiting, headache, dizziness, hypotension, pruritus, pain in extremity, arthralgia, back pain, muscle cramp, injection site reactions, chest pain, and peripheral edema. Pediatric patients: The most common adverse reactions (≥2%) are headache, respiratory tract viral infection, peritonitis, vomiting, pyrexia, dizziness, cough, nausea, arteriovenous fistula thrombosis, hypotension, and hypertension.
Source: US FDA prescribing information
Venofer may reduce the absorption of concomitantly administered oral iron preparations.
Source: US FDA prescribing information
Store in original carton at 20°C to 25°C (68° F to 77° F), excursions permitted to 15° to 30°C (59° to 86°F). Do not freeze. Intravenous Admixture Stability: Venofer, when added to intravenous infusion bags (PVC or non-PVC) containing 0.9% NaCl at concentrations ranging from 1 mg to 2 mg of elemental iron per mL, has been found to be physically and chemically stable for 7 days at controlled room temperature (25°C ± 2°C). Storage Contains no preservatives.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
7 presentations of Iron sucrose, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Iron sucrose 100 mg/5 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Venofer 100 mg/5 mL injectionIntravenous | American Regent | US FDA | Available on request |
| Iron sucrose 50 mg/2.5 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Venofer 50 mg/2.5 mL injectionIntravenous | American Regent | US FDA | Available on request |
| Iron sucrose 200 mg/10 mL injectionIntravitrealGeneric name | — | US FDA | Available on request |
| Iron sucrose 200 mg/10 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Venofer 200 mg/10 mL injectionIntravenous | American Regent | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 6 November 2000 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Iron sucrose in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 7 presentations of Iron sucrose and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Iron sucrose, including Venofer.
Yes. The US FDA first approved Iron sucrose on 6 November 2000, according to Drugs@FDA.
No listed presentation of Iron sucrose is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Iron sucrose is classified under ATC code B03AB02 (Iron sucrose).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.